These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 3053897)

  • 21. The immunosuppressive activity of L-leucyl-L-leucine methyl ester: selective ablation of cytotoxic lymphocytes and monocytes.
    Thiele DL; Lipsky PE
    J Immunol; 1986 Feb; 136(3):1038-48. PubMed ID: 2934477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surface markers of T cells causing lethal graft-vs-host disease to class I vs class II H-2 differences.
    Korngold R; Sprent J
    J Immunol; 1985 Nov; 135(5):3004-10. PubMed ID: 3876371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Graft-vs-host reaction limited to a class II MHC difference results in a selective deficiency in L3T4+ but not in Lyt-2+ T helper cell function.
    Moser M; Mizuochi T; Sharrow SO; Singer A; Shearer GM
    J Immunol; 1987 Mar; 138(5):1355-62. PubMed ID: 2949013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
    Korngold R; Leighton C; Mobraaten LE; Berger MA
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic T lymphocyte response to minor H-42a alloantigen in H-42b mice: clonal inactivation of the precursor cytotoxic T lymphocytes by veto-like spleen cells that express the H-42a antigen.
    Ishikawa H; Hino T; Kato H; Suzuki H; Saito K
    J Immunol; 1986 Oct; 137(7):2080-8. PubMed ID: 3489752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production.
    Shustov A; Nguyen P; Finkelman F; Elkon KB; Via CS
    J Immunol; 1998 Sep; 161(6):2848-55. PubMed ID: 9743345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonresponsiveness to the male antigen H-Y in H-2 I-A-mutant B6.C-H-2bm12 is not caused by defective antigen presentation.
    de Waal LP; de Hoop J; Stukart MJ; Gleichmann H; Melvold RW; Melief CJ
    J Immunol; 1983 Feb; 130(2):655-60. PubMed ID: 6401303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antigen presentation by Langerhans cells in vivo: donor-derived Ia+ Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens.
    Peeler JS; Niederkorn JY
    J Immunol; 1986 Jun; 136(12):4362-71. PubMed ID: 3519767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of TNF in hepatic histopathological manifestations and hepatic CD8+ T cell alloresponses in murine MHC class I disparate GVHD.
    El-Hayek JM; Rogers TE; Brown GR
    J Leukoc Biol; 2005 Oct; 78(4):1001-7. PubMed ID: 16081594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autoimmunity following neonatal tolerance to alloantigens: role of donor I-A and I-E molecules.
    Kramar G; Schurmans S; Berney M; Izui S; del Giudice G; Lambert PH
    J Autoimmun; 1995 Apr; 8(2):177-92. PubMed ID: 7612147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abrogation of hybrid resistance to bone marrow engraftment by graft-vs-host-induced immune deficiency.
    Hakim FT; Shearer GM
    J Immunol; 1986 Nov; 137(10):3109-16. PubMed ID: 3095424
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of graft-versus-host disease on anti-tumor immunity.
    Schreiber KL; Forman J
    J Immunol; 1990 Mar; 144(5):2018-26. PubMed ID: 1968493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Split tolerance in spleen chimeras.
    Sprent J; Hurd M; Schaefer M; Heath W
    J Immunol; 1995 Feb; 154(3):1198-206. PubMed ID: 7822792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protection from lethal graft-vs.-host disease by donor stem cell repopulation.
    Rozendaal L; Pals ST; Melief CJ; Gleichmann E
    Eur J Immunol; 1992 Feb; 22(2):575-9. PubMed ID: 1347016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
    Brochu S; Baron C; Hétu F; Roy DC; Perreault C
    J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Keratinocytes synthesize Ia antigen in acute cutaneous graft-vs-host disease.
    Breathnach SM; Katz SI
    J Immunol; 1983 Dec; 131(6):2741-5. PubMed ID: 6417231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generalized toxicity of L-leucyl-leucine-methyl ester for lymphocyte functions.
    Mowat AM; Leck PA
    Immunology; 1990 Apr; 69(4):564-9. PubMed ID: 2335375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.